Mar 25, 2021
Two months after acquiring an AI engine it claims can potentially speed up drug development by “unprecedented” levels,” AbSci has secured a hefty crossover round to integrate the engine into the company. And it has CEO Sean McClain considering an eventual IPO. AbSci...
Mar 25, 2021
Round was co-led by Casdin Capital and Redmile Group Fidelity Management & Research Company LLC, D1 Capital Partners, and Perceptive Advisors are among the new investors. VANCOUVER, Wash., March 23, 2021 /PRNewswire/ — AbSci, a pioneering synthetic biology...
Mar 8, 2021
AUSTIN, Texas, March 8, 2021 /PRNewswire/ — L7 Informatics, a leader in enterprise-scale digital transformation and automation of scientific processes in the life sciences and healthcare domains, announced that it closed its Series B financing round. The...
Mar 3, 2021
Jim Sherblom has joined ReForm Biologics as chair to lead a new strategy. The ex-Genzyme executive arrives at ReForm as it switches focus to the development of subcutaneous versions of intravenous products. In recent years, ReForm has worked on proprietary excipients...
Feb 25, 2021
ReForm Biologics Expands Focus to Develop In-house Pipeline of Bio-innovative Medicines WOBURN, Mass. – February 25, 2021– ReForm Biologics today announced it will expand its focus to develop a new generation of bio-innovative biologic medicines in-house to improve...
Feb 5, 2021
Infectious diseases diagnostics company Lucira Health Inc. launched an IPO of 9 million shares of common stock at $17 per share, for expected gross proceeds of $153 million. Friday’s Wall Street debut was a show of confidence, upsized from an original plan to offer...
